ANXA11 has also been associated with chemotherapy response in metastatic colorectal cancer, and ANXA11 nsSNP rs1049550 has been proposed as a biomarker to predict bevacizumab sensitivity in these patients (Kim et al., 2011, 2013; Roh et al., 2016). This evidence concerns the gene ANXA11 and metastatic colorectal cancer.